Healthcare Private Placement and M&A Transactions Review Week Ending December 14, 2025

Impulse Dynamics: The company raised $158 million of venture funding from Redmile Group, Sands Capital and Perceptive Advisors on December 10, 2025. Alger, Braidwell and other undisclosed investors also participated in the round. The company is a developer of a cardiac contractility modulation technology designed to treat chronic heart failure problems.

BlossomHill Therapeutics: The company raised $84 million of Series B venture funding in a deal led by Brahma Capital, BioTrack Capital and Janus Henderson Investors on December 10, 2025. Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules Bioventures, Plaisance Capital Management, H&D Asset Management and Colt Ventures also participated in the round. The company is an operator of a biopharmaceutical business designed to develop treatments for oncology and autoimmune diseases.

Edison Scientific: The company raised $65.8 million of venture funding from undisclosed investors on December 9, 2025. The company is a developer of AI-powered autonomous research platforms providing literature synthesis, data analysis, and hypothesis generation for scientific discovery.

Relation: The company closed on $55 million of an undisclosed targeted amount of venture funding on December 9, 2025. The company is a provider of biotechnology therapeutics for diseases with significant unmet medical needs across multiple therapeutic areas.

Cresilon: The company raised $48.6 million of Series A venture funding from Catalio Capital Management, William Paseman and other undisclosed investors on December 8, 2025. The company is a developer of plant-based hemostatic gel products promoting natural clotting and rapid wound healing for trauma care.

PsiThera: The company raised $47.5 million of Series A venture funding in a deal led by Lightstone Ventures and Samsara BioCapital on December 10, 2025. Eurofarma Ventures, Roivant Sciences and YK Bioventures also participated in the round. The company is a developer of physics-driven drug discovery platforms accelerating therapeutic design through computational modeling.

EpilepsyGTX: The company raised $33 million of Series A venture funding from British Business Bank, XGEN Venture and other undisclosed investors on December 10, 2025. The company is a developer of gene therapies designed for neurological disorder treatment.

Alphyn: The company raised $25 million of Series B venture funding in a deal led by Queen City Angels on December 12, 2025. Serial Stage Venture Partners, Angel Star Ventures and other undisclosed investors also participated in the round. The company is a developer of bioactive therapeutics for severe and prevalent skin diseases including inflammatory conditions.

Cambrian Bio: The company raised $23 million of venture funding from Korify Capital, FJ Labs and Sprint VC on December 12, 2025. Calm Ventures, Mount Nebo Capital, Gaingels, Shake and Bake, Care Bear, Richard Dulude, RA Capital Management and SV Pacific Ventures also participated in the round. The company is a developer of therapeutics targeting biological mechanisms of aging and age-related disease prevention.

Relentless Health: The company raised $20.7 million of venture funding from undisclosed investors on December 9, 2025. The company is an operator of an artificial intelligence health data platform intended to facilitate early disease prevention through predictive analytics.

Bioxodes: The company raised EUR 17.5 million of Series A venture funding from Newton BioCapital and other undisclosed investors on December 10, 2025. The company is an operator of a clinical-stage biopharmaceutical business intended to prevent and treat thrombotic and inflammatory diseases.

Consano Bio: The company raised $16.8 million of venture funding in the form of convertible debt from undisclosed investors on December 12, 2025. The company is a developer of biologic therapeutics for orthopedic conditions, providing disease-modifying cartilage regeneration treatments.

Pan Cancer T: The company raised EUR 10 million of venture funding from Erasmus MC, InnovationQuarter, and Thuja Capital Management on December 8, 2025. Van Herk Groep also participated in the round. The company is a developer of T-cell therapies designed to provide treatment options for hard-to-treat solid cancers through adoptive therapy.

Lin Health: The company raised $11 million of Series A venture funding in a deal led by Proofpoint on December 9, 2025, putting the company’s pre-money valuation at $29 million. Viola Ventures, Saban Ventures, Mayo Clinic Ventures, NewHealth Ventures, Osage Venture Partners, Shoni Health Ventures and aMoon Fund also participated in the round. The company is a developer of a digital, integrated behavioral health therapy platform designed to offer diagnosis and treatment for people suffering from chronic pain.

uMethod: The company raised $4.5 million of venture funding in the form of convertible debt from undisclosed investors on December 8, 2025. The company is a provider of evidence-based, personalized treatment plan services intended to treat chronic diseases.

NeuroBionics: The company raised $4.25 million of venture funding from undisclosed investors on December 10, 2025. The company is a developer of a neural interface technology designed to enhance the integration of bioelectronics with the human body.

Auxilium Biotechnologies: The company raised $3.9 million of venture funding from undisclosed investors on December 11, 2025, putting the company’s pre-money valuation at $88.7 million. The company is an operator of a biotechnology business intended to treat traumatic injuries of the nervous system.

Etheros Pharmaceuticals: The company raised an undisclosed amount of venture funding from Backed VC and Immortal Dragons on December 9, 2025. The company is a developer of small-molecule drugs designed to mimic endogenous enzymes for neuroprotection and healthspan improvement.

InduPro: The company raised an undisclosed amount of venture funding from Sanofi on December 10, 2025. The company is an operator of a biopharma business intended to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.

Noah Labs: The company raised an undisclosed amount of venture funding from Catalpa Ventures on December 9, 2025. The company is a developer of software-based medical devices designed to offer voice-based machine learning software for the early detection of heart failure.

Ryght AI: The company raised an undisclosed amount of venture funding from Accenture on December 11, 2025. The company is a developer of an enterprise-scale platform designed to utilize generative artificial intelligence for real-time biopharma discovery.

Senderra RX Partners: The company entered into a definitive agreement to receive an undisclosed amount of development capital from Nautic Partners on December 10, 2025. The company is a U.S. provider of specialty pharmacy services serving patients, prescribers, payers, and pharmaceutical partners.

Stellus Rx: The company received an undisclosed amount of development capital from WindRose Health Investors on December 8, 2025. The company is a provider of personalized pharmacy services intended to serve patients, healthcare providers, and risk-bearing entities.

Merus / Genmab: The company was acquired by Genmab for approximately $7.4 billion on December 12, 2025. Merus NV is a clinical-stage immuno-oncology company that develops bispecific antibody therapeutics.

Orbital Therapeutics / Bristol-Myers Squibb: The company was acquired by Bristol-Myers Squibb for $1.5 billion on December 8, 2025. The company is a developer of RNA therapeutics platforms integrating delivery mechanisms and modalities for genetic medicine.

Teleflex Medical OEM / Kohlberg & Company: The company entered into a definitive agreement to be acquired by Kohlberg & Company and Montagu Private Equity through a $1.5 billion LBO on December 9, 2025. The company is a manufacturer of medical-device components and interventional systems intended for use in diagnostic and therapeutic procedures.

Arthrosi Therapeutics / Swedish Orphan Biovitrum: The company reached a definitive agreement to be acquired by Swedish Orphan Biovitrum, a subsidiary of AstraZeneca, for up to $1.5 billion on December 13, 2025. The company is a developer of biotechnology drugs designed to reduce flare and tophi in gout patients.

Bluejay Therapeutics / Mirum Pharmaceuticals: The company reached a definitive agreement to be acquired by Mirum Pharmaceuticals for $820 million on December 8, 2025. The company is a developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases.

Medical Manufacturing Technologies / Perimeter Solutions: The company entered into a definitive agreement to be acquired by Perimeter Solutions, via its financial sponsors Berkshire Partners, Meritage Funds, Tiger Global Management, Principal Global Investors, Select Equity Group, The WindAcre Partnership, Tiger Eye Capital, Eminence Capital, Janus Henderson Investors, and Matrix Capital Management, through a $685 million LBO on December 10, 2025. The company is a manufacturer of automated manufacturing equipment and precision tools for the medical device industry.

Adverum Biotechnologies / Eli Lilly: The company was acquired by Eli Lilly for up to $262 million on December 9, 2025. The company is a developer of gene therapies for prevalent ocular diseases including diabetic macular edema.

Alexza Pharmaceuticals / Lee’s Pharmaceutical Holdings: Lee’s Pharmaceutical Holdings reached a definitive agreement to acquire the Staccato One Breath Platform Technology of Alexza Pharmaceuticals for $15 million on December 9, 2025. The company is a developer of aerosol drug delivery platforms enabling rapid pulmonary administration of pharmaceuticals.

Applied Therapeutics / Cycle pharma: The company reached a definitive agreement to be acquired by Cycle pharma for an undisclosed amount on December 11, 2025. The company is a developer of novel therapeutics targeting validated molecular pathways in high unmet medical need indications.

iFocus Health / HarmonEyes: The company was acquired by HarmonEyes for an undisclosed amount on December 10, 2025. The company is a developer of digital health platforms measuring the effectiveness of ADHD treatments through objective assessments.

O.R. Trax / Banyan Software: The company was acquired by Banyan Software, via its financial sponsors Pacific Lake, Norwest, Rock Creek Capital, and Ares Management, through an LBO on December 8, 2025 for an undisclosed amount. The company is a developer of vendor and visitor credentialing software for healthcare facilities that excludes protected health information.

P1 Trials / Pratia: The company was acquired by Pratia, a subsidiary of Neuca, for an undisclosed amount on December 8, 2025. The company is a developer of clinical trial support services designed for early-phase oncology research purposes.

Safepath Laboratories / KVP International: The company was acquired by KVP International, via its financial sponsor Carmelina Capital Partners, through an LBO on December 12, 2025 for an undisclosed amount. The company is an operator of diagnostic laboratories specializing in rapid test development, research, and manufacturing for veterinary and human health.

Samarit Medical / PHS Group: The company was acquired by PHS Group for an undisclosed amount on December 12, 2025. The company is a manufacturer of patient handling and mobility products intended to serve healthcare facilities and home care markets.

Xanitos / Bessemer Investors: The company was acquired by Bessemer Investors through an LBO on December 9, 2025 for an undisclosed amount. The company is a provider of hospital support services including environmental services, patient transportation, and facility operations.